IMPROVING THE LIVES OF PATIENTS WITH BRAIN TUMORS 

©2019 GT Medical Technologies, Inc. I All Rights Reserved 

  • LinkedIn Social Icon
  • Twitter Social Icon

GammaTile  Therapy

TM

GammaTile Therapy  |  STaRT

GammaTile Therapy is a safe and effective Surgically Targeted Radiation Therapy (STaRT) that begins working immediately at the time of brain tumor removal.[1]

  • FDA-cleared for treating recurrent brain tumors, including meningiomas, metastases, high-grade gliomas, and glioblastomas​

  • Extends survival and delays tumor recurrence for patients with recurrent brain tumors[1]

  • Patients receive radiation treatment while going about their daily lives

Extended Local Recurrence-Free and Overall Survival

In a clinical study, GammaTile Therapy gave the average patient approximately 10 extra months without a local recurrence with extended overall survival.[1]

  • Taken as a whole group (across all tumor types in the clinical study), patients who received surgery plus GammaTile Therapy had an approximately 2X improvement in median time to tumor recurrence compared to their most recent prior treatment.[1.*]

  • The median time to surgical-site brain tumor recurrence was 19.9 months, a 9.7-month improvement across all tumor types in the clinical study.[1.*]

* Tumor types in the clinical study were high-grade gliomas, meningiomas, and brain metastases.

~2X IMPROVEMENT ACROSS ALL

TUMOR TYPES IN THE STUDY[1]

Median local control (LC) after GammaTile Therapy vs prior treatment was 12.0 vs 9.5 months for high-grade glioma (HGG) patients (HR 0.6, p = .13) and 48.8 vs 23.3 months (HR 0.24, p = .01) for meningioma patients. For the metastasis patients, the median LC has not been reached vs 5.1 months with prior treatment (HR .07, p = 0.02).[1] The median overall survival (OS) was 12.0 months for HGG patients, 12.0 months for the brain metastasis patients, and 49.2 months for the meningioma patients.[1]

EXTENDED OVERALL SURVIVAL: RECURRENT GLIOMA[1-3]

Find a GammaTile Therapy Center near you or Contact Us to learn more.

REFERENCES

  1. Data on file, GT Medical Technologies.

  2. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment  modality. Euro J Cancer. 2012; 48(14):2192-2202.

  3. Shi W, Bryan MS, Gilbert MR, et al. Investigating the effect of reirradiation or systemic therapy in patients with glioblastoma after tumor progression: a secondary analysis of NRG oncology /Radiation Therapy Oncology Group Trial 0525. Int J Radiation Oncol Biol Phys. 2018;100(1):38-44.